Biolife Solutions executive sells shares worth $33,275

Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold 1,331 shares of the company’s common stock. The transaction, executed on March 11, 2025, was conducted at a price of $25 per share, amounting to a total value of $33,275. Following this sale, Foster retains ownership of 154,912 shares. The sale occurred with the stock trading near its 52-week high of $29.55, in a year that has seen BLFS shares gain nearly 50%. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 4.54x and operates with a moderate debt level.

According to the filing, the sale was made under a Rule 10b5-1 trading plan, which was adopted to address tax withholding obligations related to the vesting of restricted stock. With a market capitalization of $1.17 billion, BioLife Solutions shows mixed signals - InvestingPro data reveals 7 additional key insights about the company’s financial health and growth prospects, available in the comprehensive Pro Research Report.

In other recent news, BioLife Solutions reported robust financial results for the fourth quarter of 2024, with total revenue reaching $22.7 million, surpassing analysts’ estimates. The company posted a net loss of $2.0 million, or $0.04 per share, which was smaller than anticipated. BioLife’s Cell Processing segment, a major contributor to its performance, experienced a 31% year-over-year increase in revenue, amounting to $20.3 million. This marked the fifth consecutive quarter of revenue growth for the segment.

Analyst firm H.C. Wainwright raised the price target for BioLife Solutions to $30, maintaining a "Buy" rating, while Benchmark also reiterated a Buy rating with the same price target. Both firms highlighted the company’s strong financial performance and positive future outlook. BioLife Solutions has projected 2025 revenue to range between $95.5 million and $99 million, indicating a 16-20% growth over the previous year. The company anticipates its Cell Processing revenue to grow between 18% and 21%, reflecting confidence in its continued operational efficiency and market position.

Moreover, BioLife Solutions has incorporated its biopreservation media into 17 approved cell and gene therapies, with expectations for further approvals and expansions in the next 12 months. The company has also completed the sale of a non-core product line to focus on enhancing gross margin and adjusted EBITDA margin.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.